cancer trial

Oct 8, 2024, 13:11 | Blog

Elisa Agostinetto: The practice-changing results of the HypoG-01 UNICANCER trial at ESMO24

Elisa Agostinetto shared a post by MediMix, on X, adding: ''At ESMO24 the practice-changing results…

Oct 1, 2024, 08:28 | Blog

Daniel Michaeli: Key takeaways from our new article on breast cancer drugs

Daniel Michaeli shared a post on LinkedIn, about a recently published paper: Breast cancer drugs:…

Sep 26, 2024, 15:35 | Blog

Jarushka Naidoo: TL01 Phase III Datopotamab-Deruxtecan vs Docetaxel in second-line NSCLC

Jarushka Naidoo shared a post on X, about recent paper published in Journal of Clinical…

Sep 26, 2024, 14:27 | Blog

Mehdi Hamadani: Efficacy of axatilimab in chronic graft-versus-host disease

Mehdi Hamadani shared a post on X, about recent paper published in The New England…

Sep 24, 2024, 23:18 | Blog

Giuseppe Lombardi: Pleased to announce the academic MIRAGE trial for patients with recurrent grade 2-3 meningioma

Giuseppe Lombardi, Head of the Neuro-Oncology Unit at the Veneto Institute of Oncology, shared a…

Sep 24, 2024, 16:52 | Blog

Assessment of the safety and efficacy of Balstilimab in combination with Botensilimab for NSCLC - Immune Oncology Research Institute

Immune Oncology Research Institute shared a post on LinkedIn: ''Assessment of the safety and efficacy…

Sep 24, 2024, 11:46 | Blog

David Palma: Final results of ORATOR, after completion of the full follow-up period

David Palma shared a post on X, about recent paper published in Journal of Clinical…

Sep 22, 2024, 12:38 | Blog

Amol Akhade: Cabozantinib plus Atezolizumab vs second-line NHT in prostate cancer

Amol Akhade shared a post on LinkedIn: ''Cabozantinib plus Atezolizumab versus second-line Non-hormonal Therapy (NHT)…

Sep 21, 2024, 14:16 | Blog

Sabine D. Brookman-May: The right questions addressed by Petros Grivas after NIAGARA trial presentation

Sabine D. Brookman-May shared a post by Roberto Iacovelli, on X, adding: ''The right questions…

Sep 21, 2024, 13:07 | Blog

Olubukola Ayodele about HER2 low breast cancer

Olubukola Ayodele shared a post on LinkedIn: ''Let's talk about HER2 low breast cancer. The…

Sep 21, 2024, 13:02 | Blog

Final OS data from the phase III CONTACT-02 trial at ESMO24

ESMO (European Society for Medical Oncology) shared a post on LinkedIn: ''Final OS data from…

Sep 21, 2024, 09:03 | Blog

Neoadjuvant nivolumab with or without ipilimumab in early stage TNBC

Top Biomedical Science shared a post on X, about recent paper published in Nature Medicine:…

Sep 17, 2024, 16:11 | Blog

Amol Akhade: ESMO Presidential Today - Keynote 522 Shows Overall Survival

Amol Akhade shared a post on LinkedIn: ''ESMO presidential today. Keynote 522 shows overall survival…

Sep 10, 2024, 13:45 | Societies

Rami Manochakian's key highlights from WCLC24

WCLC is a major international event focused on the latest advancements in lung cancer research,…

Jul 29, 2024, 07:15 | Blog

Petros Grivas discusses the SURE -01 and the TROPICS-04 trials with Chandler Park

Chandler Park shared a post on X: ''Petros Grivas and I discuss the SURE -01 and…

Jul 20, 2024, 10:51 | Blog

Toni Choueiri: TiNivo2 results are out

Toni Choueiri shared a post on X: ''TiNivo2 results are out - adding PD1 inhibitor…

Jul 16, 2024, 23:34 | Blog

Integrating Clinical Trials and Practice - A New JAMA Series and Call for Papers

JAMA shared a post on X: ''JAMA invites articles for new article series, 'Integrating Clinical…

Jul 14, 2024, 22:08 | Blog

The primary endpoint has been reached in the EORTC-1333-GUCG/PEACE III Trial

EORTC (European Organisation for Research and Treatment of Cancer) shared a post on X: ''EORTC…

Jul 14, 2024, 06:27 | Blog

Georges Gebrael: Baseline bone pain associated with lower survival in mHSPC

Georges Gebrael, Research Fellow at Huntsman Cancer Institute and University of Utah, shared on X/Twitter:…

Jul 11, 2024, 16:10 | Blog

Roupen Odabashian: Customer Service in Healthcare

Roupen Odabashian shared a post on LinkedIn: ''Customer Service in Healthcare. Today, for the first time…

Jul 8, 2024, 08:55 | Blog

Stefano Arcangeli: Our one-shot single-session radiotherapy for UIR and HR PCa is finally out on IJROBP - The Red Journal

Valeria Faccenda, Medical Physicist at IRCCS San Gerardo dei Tintori Foundation, shared a post by…

Jun 18, 2024, 18:23 | Insight

Matthias Guckenberger: Cancer trial participation not associated with longer OS compared to routine care

Matthias Guckenberger, Radiation Oncologist at University Hospital Zurich, shared on X: “Cancer trial participation not…

Jun 6, 2024, 00:54 | Blog

Discussing the practice changing LAURA trial - Two Onc Docs

Two Onc Docs shared a post on X/Twitter: ''Discussing the practice changing LAURA trial for…

May 16, 2024, 12:26 | Blog

Michael Chuong: The agenda for this pancreatic cancer conference looks great

Michael Chuong, Lead GI Radiation Oncologist at Miami Cancer Institute, shared on X/Twitter: ''The agenda…

May 14, 2024, 13:53 | Blog

John Edwards: Lots of debate about the MARS2 RCT of mesothelioma surgery since Eric Lim’s presentation at IASLC

John Edwards, Consultant Thoracic Surgeon at Sheffield Teaching Hospitals NHS Foundation Trust and Member Board…

May 5, 2024, 07:31 | Blog

Pavlos Msaouel: Interpreting randomized controlled trials

Pavlos Msaouel, Medical Oncologist in the GU Department at MD Anderson Cancer Center, shared a…

Apr 17, 2024, 17:16 | Insight

Rafeh Naqash: Fantastic discussion on biomarker testing and precison oncology

Pashtoon Kasi, Oncologist and Researcher at Weill Cornell Medicine, replied to the post of Rafeh…

Apr 3, 2024, 06:35 | Opinion

Pashtoon Kasi: ctDNA kinetics is going to be an important variable to look at in patients getting novel immunotherapy drugs like the BOT/BAL on our NEST trial

Pashtoon Kasi, Director for Colorectal Cancer Research at Weill Cornell Medicine, shared on X/Twitter: ''ctDNA…

All: 28 Posts: 1 - 100

cancer trial

OncoDaily

cancer trial